Trump looks to hammer down drug prices with 4 executive orders – Endpoints News

President Donald Trump signed 4 executive orders targeting the pharmaceutical industry Friday afternoon, four months before voters head to the polls.

The presidential directives are part of Trumps long-standing goal to reduce prescription drug prices in the US. As the calendar turns toward November, the president has shifted to executive action over working with Congress to reach this objective.

Whether or not such action will result in any meaningful changes before the election remains to be seen, as thepharma industry continues to be a lobbying force on Capitol Hill. The executive orders are also likely to be challenged in court.

The most controversial order reportedlyattempts to cap some prices Medicare pays to the price in foreign countries, which are usually significantly lower. The text wasnt immediately available.

These most-favored nations clauses are akin to price controls in pharma circles, and Trump threatened drug companies by imposing this order within a month if the companies didnt lower prices on their own. How Trump can enact the clause without Congress remains unclear.

One of pharmas most influential lobbyist groups, PhRMA, unsurprisingly reacted negatively to the developments. Heres PhRMA president Stephen Ubl:

In his 2020 State of the Union Address, President Trump declared that we will never let socialism destroy American health care.

Yet, in the middle of a global pandemic, when nearly 145,000 Americans have lost their lives and millions of others have suffered untold economic hardships, this administration has decided to pursue a radical and dangerous policy to set prices based on rates paid in countries that he has labeled as socialist, which will harm patients today and into the future.

The research-based biopharmaceutical industry has been working around the clock to develop therapeutics and vaccines to treat and prevent COVID-19. The administrations proposal today is a reckless distraction that impedes our ability to respond to the current pandemic and those we could face in the future. It jeopardizes American leadership that rewards risk-taking and innovation and threatens the hope of patients who need better treatments and cures.

The presidents attempt to open our country up to socialized health care sets America, our economic recovery and scientific progress back at a time when we need them most.

BIOs chief Michelle McMurry-Heath also slammed the move, saying she was dumbfounded that the Trump administration would seek to cripple the industry trying to end the COVID-19 pandemic.

During the press conference Trump said top pharma executives will meet with administration officials next week.

A second order is an extension of a plan introduced late last year that would allow states, drug wholesalers and pharmacies to re-import drugs from Canada at a lower cost. Pharma lobbyists claim that such plans would not be able to guarantee the safety of the US drug supply chain, a stance that has been met with skepticism, while Canada isnt particularly interested in acting as a proxy between drug companies and states.

The other two orders target insulin pricing and the rebates drug wholesalers and pharmaceutical benefit managers receive when selling to insurers.

The lobbyist group PCMA has already come out in opposition to the latter measure, with president JC Scott saying in a statement, This policy does nothing to address drug prices, it only serves to create uncertainty and raise premiums for seniors while imposing nearly $400 billion in additional taxpayer costs, all at a time when taxpayers are already footing additional costs to counter the pandemic and the national debt is at record levels.

Drug prices have been a pet issue for Trump, and the president reportedly expressed his frustration with HHS secretary Alex Azar in January saying the Democratic Party will kill us on the issue. The COVID-19 pandemic has further complicated the issue, as Trumps approval regarding how hes handling the coronavirus is deep in the red, and the White House has been funneling cash into the industry to fuel the research and development of potential vaccines.

Read more:
Trump looks to hammer down drug prices with 4 executive orders - Endpoints News

Stem Cell Assay Market Growth, Size, Analysis, Outlook by 2020 Opportunities and Forecast to 2027 – Market Research Posts

Stem Cell Assay Market Report is an objective and comprehensive study of the current state expected at the major drivers, market strategies, and key vendors growth. The study also includes the important achievements of the market, Research & development and regional growth of the leading competitors operating in the market.

This report also explain the numerous factors that form a significant element of the market. It includes the definition and the scope of the market with a detailed explanation of the market drivers, opportunities, restraints, and threats.

Get Sample Report (including full TOC, Tables and Figures): https://www.coherentmarketinsights.com/insight/request-sample/1632

Leading players of Stem Cell Assay Market:

Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International.

Stem Cell Assay Geographical Segmentation Includes:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of L.A.)

Middle East and Africa (Turkey, GCC)

The research report includes an exploration of the competitive landscape present in the Stem Cell Assay Market. It includes an import of the current and future trends that players can invest in. Likewise, it also includes an estimation of the business outlooks of the players and explains the nature of the competition.

Stem Cell Assay Market Segmentation

By Product Type-InstrumentsReagents & KitsBy Cell Type Adult Stem CellsInduced Pluripotent Stem CellsMesenchymal Stem CellsNeural Stem CellsHematopoietic Stem CellsUmbilical Cord Stem CellsHuman Embryonic Stem CellsBy Process Cell CultureEngineeringDifferentiationCharacterizationOthersBy Application -ResearchDrug Discovery & DevelopmentRegenerative Medicine

The plus point of this research study is that it includes the impact of COVID-19 to the Stem Cell Assay market. The data summarized within this research study includes forecast from 2020 to 2027. COVID-19 has significantly impacted each and every market on the global platform. If you have any specific requirement then Please get in touch with us. Our Expert team will provide as per report customized to your requirement.

[**NOTE: Enquiry before Buying option enables you to share your queries, in advance to procure the report. Kindly fill the enquiry form, and one of our consultants would get in touch with you to discuss the queries and would address them.]

Else place an Inquire before Purchase GlobalStem Cell Assay Market Size, Share, Growth, and Forecast 2027 @https://www.coherentmarketinsights.com/insight/request-customization/1632

Important Features of the report:

Reasons for buying this report:

It offers the regional analysis of the Stem Cell Assay Market along with the business profiles of several stakeholders.

Some Major TOC Points:

Chapter 1. Stem Cell Assay Market Report Overview

Chapter 2. Stem Cell Assay industry Growing Trends

Chapter 3. Market Share by Key vendors

Chapter 4. Stem Cell Assay Market Breakdown Data by Type and Application

Chapter 5. Stem Cell Assay Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Stem Cell Assay Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Factors

And Many More

Buy this Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/1632

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, LATAM, West Europe, MENA Countries, Southeast Asia or Asia Pacific.

Contacts US

Mr. Shah Email:[emailprotected] Phone: US +1-206-701-6702/UK +44-020 8133 4027

Visit link:
Stem Cell Assay Market Growth, Size, Analysis, Outlook by 2020 Opportunities and Forecast to 2027 - Market Research Posts

Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors – BioSpace

HOUSTON, July 28, 2020 /PRNewswire/ --Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that enrollment has commenced in its multicenter Phase 2a dose expansion clinical study of Tegavivint, a novel, potent and selective nuclear -catenin inhibitor, in patients with desmoid tumors. The Phase 2a trial builds on a recently completed open-label, non-randomized Phase 1 study that established safety and initial clinical efficacy of Tegavivint in patients with progressive desmoid tumors.

Nuclear -catenin is a highly-studied oncology target associated with numerous cancer types. Tegavivint is unique among nuclear -catenin inhibitors in that it binds to TBL1 (Transducin eta-like Protein One), a novel downstream target in the Wnt-signaling pathway. As such, Tegavivint enables silencing of Wnt-pathway gene expression without affecting other Wnt/-catenin functions in the cell membrane, thus avoiding toxicity issues common to other drugs in this pathway.

Desmoid tumors are rare, non- metastasizing sarcomas that overexpress nuclear -catenin. An estimated 1,500 patients in the US are newly diagnosed with desmoid tumors each year. Desmoids are most commonly diagnosed in young adults between 30-40 years of age and are associated with significant morbidities, including severe pain, disfigurement, internal bleeding and organ damage, range of motion loss and, in rare cases, death. Iterion has received Orphan Drug Designation for Tegavivint to treat desmoid tumors, a disease for which there are no FDA approved therapies.

"We are very pleased to advance the clinical development of Tegavivint in desmoid tumors as this disease target is greatly underserved and provides an optimal indication for demonstrating the drug's safety and potential clinical utility in multiple cancer settings," said Rahul Aras, CEO of Iterion. "Desmoid tumors are driven primarily by nuclear -catenin signaling, a historically 'undruggable' oncology target implicated in cell proliferation, differentiation and immune evasion. Efforts to develop inhibitors of -catenin through drugging upstream targets in the Wnt-signaling pathway have been plagued by toxicity issues, greatly limiting their therapeutic use. Research suggests that these toxicity concerns can be negated by targeting TBL1, a novel downstream target necessary for -catenin's oncogenic activity. Our development plan for Tegavivint is to advance its development in desmoid tumors as a launching point for additional programs in acute myeloid leukemia, non-small cell lung cancer, and certain pediatric cancers for which nuclear -catenin signaling has been identified as a potential therapeutic target."

The Phase 2a trial in desmoid tumors is expected to enroll up to 25 patients who will be treated with the recommended Phase 2 Dose (RP2D), which was established based on pharmacokinetic exposure levels and clinical responses in the recently completed Phase 1 study.

In addition to desmoid tumors, Iterion is preparing to initiate clinical programs to investigate Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. These cancers are often characterized by nuclear -catenin overexpression, providing potential high-value target expansions for Tegavivint. The RP2D established in the desmoid tumor program is expected to be utilized in the planning and execution of the clinical trials in these additional indications, offering the potential to expedite the advancement of the individual clinical studies.

About Iterion Therapeutics Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, Tegavivint, is a potent and selective inhibitor of nuclear -catenin, a historically "undruggable" oncology target implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that Tegavivint has the potential for clinical utility in multiple cancer types. Tegavivint is currently the subject of a Phase 2a clinical trial in patients with progressive desmoid tumors. Iterion is also pursuing clinical programs in additional cancers where nuclear -catenin signaling has been shown to play a role, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. This research/clinical trial was supported with a $15.9 million grant from the Cancer Prevention & Research Institute of Texas. For more information on Iterion, please visit https://iteriontherapeutics.com.

Tiberend Strategic Advisors, Inc. Ingrid Mezo (Media) 646-604-5150 imezo@tiberend.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/iterion-therapeutics-initiates-enrollment-of-phase-2a-dose-expansion-study-of-tegavivint-in-patients-with-desmoid-tumors-301100338.html

SOURCE Iterion Therapeutics

Continued here:
Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors - BioSpace

Unproven ‘stem cell’ therapies for COVID-19 pose harm to public, says UB expert – UB Now: News and views for UB faculty and staff – University at…

Be wary of stem cell therapy as a preventative treatment for COVID-19, warns Laertis Ikonomou, a UB expert on stem cell and gene therapies.

While stem cell therapy, such as bone marrow transplantation, may be used to treat a limited number of diseases and conditions, there are currently no clinically tested or government-approved cell therapies available for the treatment or prevention of COVID-19, says Ikonomou, associate professor of oral biology in the School of Dental Medicine.

He urges the public to exercise caution as the nation experiences a rise in businesses offering direct-to-consumer, unproven and unsafe stem cell therapies that promise to prevent COVID-19 by strengthening the immune system or improving overall health.

What these patients are actually sold is false hope, he says. These businesses are continuously transforming and reinventing themselves, but the common thread is that they offer potentially dangerous treatments based on unproven science.

Ikonomou is also the chair of the International Society for Cell and Gene Therapy (ISCT) Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapy.

Stem cell therapy involves the conversion of stem cells into specific types of cells, such as heart or blood cells. These cells are then transplanted into a patient to promote healing.

While there are companies that carefully develop cell-based treatments following established regulatory and ethical standards, there has also been an explosion of businesses since the mid-2000s that advertise directly to consumers and evade regulations to provide unsafe and ineffective treatments, he says.

These businesses operate in gray regulatory areas, frequently branding stem cell therapies as medical interventions rather than therapeutic drugs to avoid the need for U.S. Food and Drug Administration (FDA) approval, Ikonomou says, adding that according to published research, there are more than 1,000 of these unsafe businesses in the U.S.

They offer purported stem cell therapies for nearly every condition imaginable, from diabetes and autism to Alzheimers disease. There are also reports of people suffering physical harm including blindness and death from unsafe stem cell interventions, such as drawing and reinjecting patients with their own fat cells, he says.

Im not surprised that a lot of these businesses went into COVID treatments, says Ikonomou. They went where the money is and took advantage of peoples fears.

The treatments range in price from a few thousand to tens of thousands of dollars, and often patients are encouraged to receive the expensive infusions every few months. Many people go into severe debt to acquire these ineffective treatments, he says.

This year, the FDA has issued several letters to offending businesses, including those advertising cell therapies for COVID-19, says Ikonomou. The Federal Trade Commission has also cracked down on misleading advertising from stem cell therapy clinics, he says.

However, many of these clinics are small and difficult to track. Patient prudence is key to avoiding harmful interventions, he says.

Ikonomou shares a list of steps the public can take to ensure a stem cell therapy is safe, proven and ethical.

Ikonomou also urges patients to share any questions they have with their physicians, who often are the gatekeepers for medical treatment. His best advice to patients: If something sounds too good to be true, it probably isnt true.

For information on safe and ethical cell therapies, visit the ISCT website.

Read more from the original source:
Unproven 'stem cell' therapies for COVID-19 pose harm to public, says UB expert - UB Now: News and views for UB faculty and staff - University at...

Gilead’s Kite snares a landmark FDA OK on a $373000 CAR-T therapy which comes with bragging rights to the first true franchise op – Endpoints News

Bob Nelsen had been quietly wondering how to eradicate viruses for years, before one day in 2015, he welcomed a pair of immunologists into the ARCH Venture Partners offices on the 34th floor of Seattles Wells Fargo Building.

Louis Picker and Klaus Frh, professors at Oregon Health & Science University, had by then spent 5 years running around the country in search of funding for their startup, TomegaVax, and Frh, at least, was nearing wits end. The Gates Foundation was interested but told them they needed other investors. Investors told them to come back with more data, pharmaceutical executives said theyre in the wrong game too little money to be made fighting infectious disease. Still, a well-connected board member named Bob More landed them a meeting with the coveted venture capitalist, and so, in a narrow conference room overlooking the Puget Sound, Picker prepared to again explain the idea he had spent 15 years on: re-engineering a benign microbe into the first vaccines for HIV and better ones for hepatitis and tuberculosis.

This lightbulb went on his head, Picker recalled in a recent interview. Most of them just didnt get it. And Bobs hit.

By that point, Nelsen was more than just a venture capitalist. Scraggly and greying but no less opinionated at 52, he was mobbed at biotech conferences, having earned a reputation for crass wisdom and uncanny foresight, for making big bets on big ideas that changed medicine. Those ideas included DNA sequencing, which he first cut a check for in the 90s, and leveraging the immune system to tackle cancer. He earned millions making billion-dollar companies.

Yet for years he had harbored an almost singular obsession: I hate viruses, he told Forbes in 2016. He told me he was pissed off at them. The obsession drove him to his first biotech investment in 1993, for an inhalable flu vaccine approved a decade later and still in use. And it drove him to invest in CAR-T as a potential cure for HIV, years before it proved a wildly effective treatment for some cancers.

Now, listening to Picker talk about T cells and antibodies and the curious biology of cytomegalovirus, Nelsen began wondering if it was time for another bet. Pickers technology was not only promising, he reasoned, it could be the basis of a company that changed how researchers approached viruses. Instead of trying to come up with an antidote for every pathogen, you could do what cancer researchers had learned to do, and harness the immune system to do the work for you.

This wasnt a popular opinion at the time. Its like the least trendy idea in the world, Nelsen told me. People would say, Why the hell are you going into infectious disease?

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

More:
Gilead's Kite snares a landmark FDA OK on a $373000 CAR-T therapy which comes with bragging rights to the first true franchise op - Endpoints News

Fun facts about South Africa Here are 25 things you probably didnt know – The South African

We already love South Africa, but here are a few more reasons to be proud of the country. From medical breakthroughs and ecological wonders to industrial and cultural factoids, here are 25 things you may not have known about our beautiful corner of the globe.

South Africa is rich in remains and artefacts of early hominids. The Cradle of Humankind was declared as aWorld Heritage siteback in 1999. It currently occupies approximately 47 000 hectares of land.

In addition,UNESCO Fossil Hominids Siteslist five separate locations and traces archaeological evidence of human evolution back to least 2.5 million years ago. ,

Some countries have deserts or grasslands, other countries have wetlands or subtropical forests. But that is no match for the country we call home.

South Africa has a diverse range of biomes: from deserts, wetlands, grasslands and bush, to subtropical forests, mountains and escarpments. In addition, our climate is as varied as our biomes, ranging from desert to subtropical weather.

Our flora and fauna are also among the most biologically diverse in the world.

Dr Chris Barnard famouslyperformed the worlds first hearttransplant in 1967 on Louis Washkansky, who volunteered for the groundbreaking surgery.

The success of the first heart transplant turned Dr Barnard into somewhat of a celebrity on the international scene, and he performed ten more transplants throughout his career.

On 3 March 2019, Professor Mashudu Tshifularo became the first person to transplant 3D-printed bones for reconstructive middle ear implants, at the Steve Biko Academic Hospital.

Prof Tshifularo, who is the head of the Department of Ear, Nose, and Throat and Head and Neck Surgery at theOtorhinolaryngologyDepartment of theUniversity of Pretoria, developed the technology during his PhD studies.

The worlds firstdigital laserwasinvented by doctoral candidate, and CSIR researcher, Dr Sandile Nqcobo, and the former minister of Science and Technology cited it as a testimony to the calibre of scientists that South Africa has.

The laser is used in the health sector, and its numerous applications could also be used to improve the communication sector.

The scanner wascreated by Lodox Systems,a South African company that created the full-body scanner from technology that was initially designed for the security sector for the detection of stolen diamonds.

The use of the full-body scanner was written into the storyline of Greys Anatomy during the shows ninth season when the Grace Mercy West Hospital installed the scanner in their new ER department.

The CSIRs Gene Expression and Biophysics groupdesigned the first induced pluripotent stem cells in Africa, which opened the door for researchers to investigate various diseases and cures.

Stem cells could be used to restore sight or repair cells affected by heart disease, amongst other things. The possibilities are endless and are still being explored.

We sure do like our booze, that is no secret. One just has to look at the uproar generated by the recent alcohol bans in South Africa amid the COVID-19 pandemic and subsequent lockdowns.

But did you know that SAs brewery, SABMiller ranks, by volume, as the largest brewing company in the world? Approximately 50% of SABs production ships off to supply Chinas beer market.

Nearly three decades after the Cold War ended, there are still about 23 000 nuclear warheads in the world. South Africas nuclear weapons programme was established in 1967.

From the late sixties to the late eighties, South Africa researchedweapons of mass destruction, including nuclear, biological and chemical weapons. The nuclear weapons programme came to an end in 1989.

However, South Africa is the first and only country in the world to have built nuclear weapons and then voluntarily dismantle its entire nuclear weapons programme.

According to Statista, South Africa is the largest producer of platinum in the world by a significant margin, with a production of between 94 and 130 metric tons each year from 2010 to 2019.

In 2014 South Africa produced approximately 110 000kg, which is more than four times the amount of the worlds second-biggest producer, Russia. The latter produced between 23 metric tons and 22 metric tons each year between 2010 and 2018.

On 25 January 1905, the Cullinan diamond was found in the Premier Mine in Pretoria, South Africa. At 603 grams (or 1.33 pounds) it was the largest diamond in the world.

The 3 106-carat stone was later cut into nine large pieces and about 100 smaller ones. The largest of the nine, the Cullinan I or Great Star of Africa, was an impressive 530.2 carats. It is currently in the Queen of Englands Sceptre. And the rest?

Until 2019, South Africa was the only country in theworld to have hosted the Soccer, Cricket and Rugby World Cup. England joined us in the ranks last year, and is also the only country to have won all three World Cups.

Nowhere else in the world will you find that two Nobel Peace Prize laureates lived on the same street. Both Nelson Mandela and Archbishop Desmond Tutu lived onVilakazi Streetin the Orlando West township in Soweto.

Desmond Tutu was awarded the Nobel Peace Prize in 1984 for his nonviolent opposition to apartheid, followed by Nelson Mandelas shared Nobel Peace Prize in 1993 with F.W. de Klerk, for their role in the peaceful end of apartheid.

Table Mountain in Cape Town is one of the oldest mountains in the world, just over 260 million years to be exact. It also has more than 2 200 species of plants and approximately 900 different routes to climb or hike.

Lets put that in perspective: Table mountain alone has more plant species than the entire United Kingdom. In addition, the Cape Floral Region represents less than 0.5% of the area of Africa, but is home to 20% of the continents flora.

Each of the eight UNESCO World Heritage Sites in South Africa reflects an important aspect of its cultural and natural landscape. Thesitesinclude cultural treasures such as hominid fossils, the earliest indigenous kingdom of South Africa, the cave paintings of the San people.

In addition, it also includes the traditional use of the land by the Nama and the prison that housed political prisoners, including Nelson Mandela. Other sites protect the natural uniqueness of South Africa from the Cape Floral Region and the iSimangaliso Wetlands to the Vredefort Dome.

Speaking of UNESCO World Heritage sites, South Africa is home to the oldest meteor scar in the world the Vredefort Dome in Parys. A meteor the size of a mountain fell to Earth around 2 030 million years ago.

The 10km-wide meteor left a crater 300km across and is the oldest crater made by either a comet or meteorite. Its also reportedly the site of the largest energy release in history.

Despite a recent Australian discovery, we can still claim the largest visible crater in the world. In 2015, scientists found a bigger crater measuring 400km wide underground in the Australian outback.

South Africas Cape Winelands is the worlds longest wine route, with a meandering road spanning 850 kilometres. Route 62 runs between Cape Town, Constantia to Port Elizabeth, via Oudtshoorn and the Garden Route, passing by 200 cellars and kilometres of vines.

The hunter-gather Sans and pastoral Khoi become known as the KhoiSan and lived in what is present-day Western Cape around 300AD. Zulu and Xhosa tribes established large kingdoms in the region during the 15th century.

The South African fish migration is so huge it can be seen from space between May and July every year. Millions of small silver fish travel in vast shoals from the cold waters off South Africas Cape Point up to the coastlines of the northern Eastern Cape and southern KwaZulu-Natal.

This annual event is known as the Sardine Run. The shoals are so big 15km long, 3.5km wide and up to 40m deep they can be seen by satellite. In their wake come hundreds of birds, sharks, whales, dolphins, all eager to catch a bite.

The Karoo region in the Western Cape is home to some of the bestfossils of early dinosaurs. In fact, it is estimated that some 80% of the mammalian fossils found to date were found in the Karoo.

The University of South Africa (Unisa) which was founded in 1873 as the University of the Cape of Good Hope is the largest correspondence university in the world.

Unisa became the first public university in the world to teach exclusively by means of distance education in 1946. Today, the university has more than 400 000 students from 130 countries.

Adrenaline junkies will be eager to fling themselves off the worlds highest commercial bridge bungee in the world at Bloukrans Bridge in the Tsitsikamma region between the Eastern and Western Cape.

At a dizzying 216 metres high, the popular jump sees thrill-seekers plunge towards the Bloukrans River below before bouncing to a stop.

For centuries, the South African coastline has claimed the lives of thousands of sailors. Today, all shipwrecks are protected under South African law. A list of the shipwrecks along the coast can be viewed here.

In 2006, South Africa became the first African country and the fifth country in the world to recognise same-sex marriage. The prohibiting of discrimination based on sexual orientation is even written into their constitution.

Cape Town is also referred to as the Gay Capital of the World.

A segment of the infamous Berlin Wall, which was torn down in November 1989, was gifted to our late president Nelson Mandela following his visit to Berlin in 1996. Today, this piece of history sits atop the St Georges Mall outside Mandela Rhodes Place.

Not only is South Africa a prime film destination, but we also have the second oldest film industry in the world. The firstfilmstudio inSouth Africa, KillarneyFilmStudios, wasestablishedin 1915 in Johannesburg; Hollywood was founded in 1903.

Some of the most famous Hollywood movies shot in South Africa include Avengers: Age of Ultron, Mandela: Long Walk to Freedom, Safe House, District 9, Blood Diamond, Homeland, Outlander, Resident Evil: The Last Chapter, The Dark Tower, Black Sails, The Maze Runner: The Death Cure and Tomb Raider.

The AngloGold Ashantis Mponeng gold mine near Johannesburg is the deepest gold mine in the world. It takes more than an hour to travel from the surface right down to the bottom.

The temperature of the rock so deep down gets very hot and the air in the tunnels is cooled by pumping slurry ice into the depths.

South Africa has 12 official languages: English, Afrikaans, isiZulu, isiXhosa, Sesotho, Setswana, Sepedi, Xitsonga, siSwati, isiNdebele, Tshivenda, and Sign Language, whichwas officially recognised as a homelanguagein 2018.

As per the 2011 census, 22.7% of South Africans speak isiZulu as their native language, making it the most commonly spoken language. English is the most common language used in business.

The only other country with more languages than South Africa is India with 18 official languages. However, each language is recognised as the official language of a certain area, and not the country as a whole.

South Africa is the only country in the world with three capitals, and no, Pretoria is not the capital. Pretoria is the administrative capital while Cape Town is the legislative capital and Bloemfontein the judicial capital.

The only city specified in the Constitution of South Africa is Cape Town, the seat of Parliament. Most foreign embassies are in Pretoria, but many countries also have consulates in the other cities.

View post:
Fun facts about South Africa Here are 25 things you probably didnt know - The South African

AbbVie backs an Italian startup focused on autoimmune diseases; BioTheryX advances AML drug with $35M D round – Endpoints News

Bob Nelsen had been quietly wondering how to eradicate viruses for years, before one day in 2015, he welcomed a pair of immunologists into the ARCH Venture Partners offices on the 34th floor of Seattles Wells Fargo Building.

Louis Picker and Klaus Frh, professors at Oregon Health & Science University, had by then spent 5 years running around the country in search of funding for their startup, TomegaVax, and Frh, at least, was nearing wits end. The Gates Foundation was interested but told them they needed other investors. Investors told them to come back with more data, pharmaceutical executives said theyre in the wrong game too little money to be made fighting infectious disease. Still, a well-connected board member named Bob More landed them a meeting with the coveted venture capitalist, and so, in a narrow conference room overlooking the Puget Sound, Picker prepared to again explain the idea he had spent 15 years on: re-engineering a benign microbe into the first vaccines for HIV and better ones for hepatitis and tuberculosis.

This lightbulb went on his head, Picker recalled in a recent interview. Most of them just didnt get it. And Bobs hit.

By that point, Nelsen was more than just a venture capitalist. Scraggly and greying but no less opinionated at 52, he was mobbed at biotech conferences, having earned a reputation for crass wisdom and uncanny foresight, for making big bets on big ideas that changed medicine. Those ideas included DNA sequencing, which he first cut a check for in the 90s, and leveraging the immune system to tackle cancer. He earned millions making billion-dollar companies.

Yet for years he had harbored an almost singular obsession: I hate viruses, he told Forbes in 2016. He told me he was pissed off at them. The obsession drove him to his first biotech investment in 1993, for an inhalable flu vaccine approved a decade later and still in use. And it drove him to invest in CAR-T as a potential cure for HIV, years before it proved a wildly effective treatment for some cancers.

Now, listening to Picker talk about T cells and antibodies and the curious biology of cytomegalovirus, Nelsen began wondering if it was time for another bet. Pickers technology was not only promising, he reasoned, it could be the basis of a company that changed how researchers approached viruses. Instead of trying to come up with an antidote for every pathogen, you could do what cancer researchers had learned to do, and harness the immune system to do the work for you.

This wasnt a popular opinion at the time. Its like the least trendy idea in the world, Nelsen told me. People would say, Why the hell are you going into infectious disease?

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Visit link:
AbbVie backs an Italian startup focused on autoimmune diseases; BioTheryX advances AML drug with $35M D round - Endpoints News

After Big Pharma abandoned infectious diseases, 5 biotech contrarians decided to go all in. Then Covid-19 changed everything – Endpoints News

Bob Nelsen had been quietly wondering how to eradicate viruses for years, before one day in 2015, he welcomed a pair of immunologists into the ARCH Venture Partners offices on the 34th floor of Seattles Wells Fargo Building.

Louis Picker and Klaus Frh, professors at Oregon Health & Science University, had by then spent 5 years running around the country in search of funding for their startup, TomegaVax, and Frh, at least, was nearing wits end. The Gates Foundation was interested but told them they needed other investors. Investors told them to come back with more data, pharmaceutical executives said theyre in the wrong game too little money to be made fighting infectious disease. Still, a well-connected board member named Bob More landed them a meeting with the coveted venture capitalist, and so, in a narrow conference room overlooking the Puget Sound, Picker prepared to again explain the idea he had spent 15 years on: re-engineering a benign microbe into the first vaccines for HIV and better ones for hepatitis and tuberculosis.

This lightbulb went on his head, Picker recalled in a recent interview. Most of them just didnt get it. And Bobs hit.

By that point, Nelsen was more than just a venture capitalist. Scraggly and greying but no less opinionated at 52, he was mobbed at biotech conferences, having earned a reputation for crass wisdom and uncanny foresight, for making big bets on big ideas that changed medicine. Those ideas included DNA sequencing, which he first cut a check for in the 90s, and leveraging the immune system to tackle cancer. He earned millions making billion-dollar companies.

Yet for years he had harbored an almost singular obsession: I hate viruses, he told Forbes in 2016. He told me he was pissed off at them. The obsession drove him to his first biotech investment in 1993, for an inhalable flu vaccine approved a decade later and still in use. And it drove him to invest in CAR-T as a potential cure for HIV, years before it proved a wildly effective treatment for some cancers.

Now, listening to Picker talk about T cells and antibodies and the curious biology of cytomegalovirus, Nelsen began wondering if it was time for another bet. Pickers technology was not only promising, he reasoned, it could be the basis of a company that changed how researchers approached viruses. Instead of trying to come up with an antidote for every pathogen, you could do what cancer researchers had learned to do, and harness the immune system to do the work for you.

This wasnt a popular opinion at the time. Its like the least trendy idea in the world, Nelsen told me. People would say, Why the hell are you going into infectious disease?

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Read the rest here:
After Big Pharma abandoned infectious diseases, 5 biotech contrarians decided to go all in. Then Covid-19 changed everything - Endpoints News

Global EPrescription Market Research Along With COVID-19 Impact Analysis, Advancement and Outlook 2027|eclinicalworks, Henry Schein, Inc., Drfirst,…

Eprescription marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 4,581.45 million by 2027 growing at a CAGR of 21.8% in the above-mentioned forecast period. The increasing focus on the lessening of fraud & abuse of controlled substances has been directly impacting the growth of eprescription market.

Some of the key players profiled in the report areHealth Fusion, Inc., EPIC Systems Corporation, GE Healthcare, eclinicalworks, Henry Schein, Inc., Drfirst, Relayhealth, CPSI, Surescripts, Cerner Corporation, Quality Systems, Inc., Medical Information Technology, Inc., Allscripts Healthcare LLC, Athenahealth, eClinicalWorks and Aprima Medical Software, Inc., among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately. Download Sample PDF Copy of Report Along With Graphs &[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-eprescription-market

EPrescription market document is an ideal guide to attain an information or key data about market, emerging trends, product usage, and motivating factors for customers, customer preferences, competitor strategies, brand positioning, and customer behaviour. This market research report delivers an analytical measurement of the main challenges faced by the business currently and in the upcoming years. Geographical areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa are also considered for the market analysis. In addition, the EPrescription market research report contains company profile, product specifications, production value, market shares and contact information of manufacturers or companies.

North America dominates the eprescription market due to the high number of government initiatives and encouragement in the region.

To know more about the study @https://www.databridgemarketresearch.com/reports/global-eprescription-market

Global EPrescription Market Drivers & Restraints:

The increasing focus on the lessening of fraud & abuse of controlled substances has been directly impacting the growth of eprescription market.

Rising government initiatives & incentive programs is expected to have a significant impact on the eprescription market in the forecast period of 2020 to 2027. Other impactful reasons for the market growth are increased usage of eprescription has been the increased focus on reducing medication errors, need to restrict rising healthcare costs and high adoption in healthcare industry due to its benefits such as better patient safety.

Moreover, rising government support along with increasing implementation of electronic prescribing and medication administration system will further cater ample opportunities that will lead to the growth of eprescription market in the above mentioned forecast period.

High cost of employment and security & workflow issues will hamper the growth of the eprescription market in the forecast period of 2020 to 2027. Lack of technological awareness will pose as a challenge towards the growth of the eprescription market in the above mentioned forecast period.

To register for digital conference click here @https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy

Segmentation: Global EPrescription Market

Eprescription market is segmented on the basis of product, usage mode, mode of delivery and end-user. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product, the eprescription market is segmented into solutions and services. Solutions segment is further segmented into integrated solutions and standalone solutions.

On the basis of usage mode, the eprescription market is segmented into handheld device and computer-based devices.

Based on mode of delivery, the eprescription market is segmented into web & cloud-based solutions and on-premise solutions.

Eprescription market has also been segmented based on the end-user into clinics, physicians, pharmacies and hospitals.

Objective of the Report

Inquire Regarding This Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-eprescription-market

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailing[emailprotected]. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research US: +1 888 387 2818 UK: +44 208 089 1725 Hong Kong: +852 8192 7475 Email:[emailprotected]

Read the original here:
Global EPrescription Market Research Along With COVID-19 Impact Analysis, Advancement and Outlook 2027|eclinicalworks, Henry Schein, Inc., Drfirst,...

Global Blood Screening Market Size, Share, Industry Growth Survey by Types, Applications and Top Key Players Enzo Biochem Inc., Meridian Bioscience,…

Data Bridge Market Research recently released a research report on the Blood Screening analysis, which studies the Blood Screening industry coverage, current market competitive status, and market outlook and forecast by 2027.This is an insightful research report that highlights key market patterns and market drivers in the present circumstance and offers on the ground bits of knowledge. The report likewise displays examination of market size, offer, and development, patterns, and value structure, measurable and definite information of the overall business.

Blood screening marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow with a CAGR of 5.75% in the above-mentioned forecast period.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-blood-screening-market

Some of the prominent participants operating in this market are Enzo Biochem Inc., Meridian Bioscience, Inc. , BD , Bio-Rad Laboratories, Inc. , Thermo Fisher Scientific Inc., BioMrieux SA, Beckman Coulter, Inc., Abbott , F. Hoffmann-La Roche Ltd , Cepheid , GRIFOLS INTERNATIONAL, S.A. , Siemens AG , Ortho Clinical Diagnostics , Immucor, Inc., Hologic Inc., among others.

To register for digital conference click here @ https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy

Segmentation:Global Blood Screening Market

By Products & Services

(Reagents & Kits, Instruments, Software & Services),

Technology

(Enzyme-Linked Immunosorbent Assay, Rapid Tests, Next-Generation Sequencing, Nucleic Acid Test, Western Blot Assay, Others),

Disease Type

(Oncology, Diabetes Mellitus, Cold & Flu, Cholesterol, Infectious Diseases, Respiratory Diseases, HIV/AIDS, Others),

End User

(Diagnostic Centers, Blood Bank, Hospitals, Clinics, Ambulatory Surgical Centers),

Geography

(North America, Europe, Asia-Pacific, South America, Middle East & Africa)

Global blood screening market is categorized based on basis of products & services, technology, disease type and end user.

Drivers:Global Blood Screening Market

RISE IN THE DEMAND OF BLOOD DONATIONS AND BLOOD DONORS:

Blood transfusion is an essential component of the health care field. It helps in saving millions of lives every year in both cases of routine and emergency conditions. Below mentioned are some of the statistics for blood donation and blood donors:

According to the World Health Organization (WHO), in 2017, it was reported that 112.5 million blood donations were collected from worldwide in which approximately half of the blood was collected from developed countries.

According to the World Health Organization (WHO), in 2017, it was reported that in 1000 people, the blood donation rate was 32.1 from high-income countries, 14.9 in upper-middle-income countries, 7.8 in lower-middle-income countries and 4.6 in low-income countries.

According to Australia Red cross blood service, 606,000 donors are there in Australia which are in 1,000 locations such as collection centres for blood donation available.

RISING PREVALENCE IN NUMBER OF DISEASES:

The prevalence of diseases and conditions such as Tuberculosis, HIV infection, Intestinal nematodes, diabetes mellitus, respiratory diseases, oncology, cholesterol, HIV/AIDS, cold & flu, infectious diseases and many others have increased considerably over a period of time. As numbers of diseases are increasing there is requirement for blood screening and diagnosis for further treatment of diseases.

According to WHO, alpha and beta thalassaemias are found to be the most common inherited single-gene disorders around the world. This disorder is with the highest prevalence with malaria at the places where it is endemic.As per the study conducted in Iran, it was estimated that approximately 8,000 pregnancies with risk takes place every year.

In 2016, according to Centers for Disease Control and Prevention (CDC), at the end of 2015, it was estimated 1.1 million persons with age 13 or older were suffering from HIV infection in the U.S. with an estimation of 162,500 (15.0%) persons whose infections had not been diagnosed.

In February 2018, according to verywell health, in South Africa 5,600,000 of people were estimated with HIV in 2009. In the total population of 53 million, the HIV prevalence for South Africa is found to be 10.6%.

Read Full Report @https://www.databridgemarketresearch.com/reports/global-blood-screening-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:[emailprotected]

Read the original here:
Global Blood Screening Market Size, Share, Industry Growth Survey by Types, Applications and Top Key Players Enzo Biochem Inc., Meridian Bioscience,...